Replying to:
Wednesday 27 December 2017
Zhang L, Wu B, and Baruchel S from the New Agent and Innovative Therapy Program, and Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada have just published in Translational Oncology a preclinical paper entitled : Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models
ALK-inhibitor crizotinib is effective in the treatment of ALK-mutated neuroblastoma, but crizotinib (...)